Mercè Boada1,2, Oscar L López3, Javier Olazarán4,5, Laura Núñez6, Michael Pfeffer7, María Paricio8, Jesús Lorites9, Gerard Piñol-Ripoll10, José E Gámez11, Fernando Anaya12, Dobri Kiprov13, José Lima14, Carlota Grifols6, Mireia Torres6, Montserrat Costa6, Jordi Bozzo6, Zbigniew M Szczepiorkowski15, Suzanne Hendrix16, Antonio Páez6. 1. Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. 3. Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 4. Neurology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 5. Memory Disorders Unit - HM Hospitals, Madrid, Spain. 6. Alzheimer's Research Group, Grifols, Barcelona, Spain. 7. Medical Services, Allied Biomedical Research Institute, Inc., Miami, Florida, USA. 8. Center for Prevention of Alzheimer´s Disease, Miami Dade Medical Research Institute, Miami, Florida, USA. 9. Medical Services, L&L Research Choices, Inc., Miami, Florida, USA. 10. Seizure Disorders Unit, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain. 11. Psychiatry Department, Galiz Research, Hialeah, Florida, USA. 12. Nephrology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 13. Apheresis Care Group and Fresenius Medical Care, San Francisco, California, USA. 14. American Red Cross Southern Blood Services Region, Atlanta, Georgia, USA. 15. Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA. 16. Pentara Corporation, Salt Lake City, Utah, USA.
Abstract
INTRODUCTION: This phase 2b/3 trial examined the effects of plasma exchange (PE) in patients with mild-to-moderate Alzheimer's disease (AD). METHODS:Three hundred forty-seven patients (496 screened) were randomized (1:1:1:1) into three PE treatment arms with different doses of albumin and intravenous immunoglobulin replacement (6-week period of weekly conventional PE followed by a 12-month period of monthly low-volume PE), and placebo (sham). RESULTS: PE-treated patients performed significantly better than placebo for the co-primary endpoints: change from baseline of Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL; P = .03; 52% less decline) with a trend for Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog; P = .06; 66% less decline) scores at month 14. Moderate-AD patients (baselineMini-Mental State Examination [MMSE] 18-21) scored better on ADCS-ADL (P = .002) and ADAS-Cog (P = .05), 61% less decline both. There were no changes in mild-AD patients (MMSE 22-26). PE-treated patients scored better on the Clinical Dementia Rating Sum of Boxes (CDR-sb) (P = .002; 71% less decline) and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) (P < .0001; 100% less decline) scales. DISCUSSION: This trial suggests that PE with albumin replacement could slow cognitive and functional decline in AD, although further studies are warranted.
RCT Entities:
INTRODUCTION: This phase 2b/3 trial examined the effects of plasma exchange (PE) in patients with mild-to-moderate Alzheimer's disease (AD). METHODS: Three hundred forty-seven patients (496 screened) were randomized (1:1:1:1) into three PE treatment arms with different doses of albumin and intravenous immunoglobulin replacement (6-week period of weekly conventional PE followed by a 12-month period of monthly low-volume PE), and placebo (sham). RESULTS: PE-treated patients performed significantly better than placebo for the co-primary endpoints: change from baseline of Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL; P = .03; 52% less decline) with a trend for Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog; P = .06; 66% less decline) scores at month 14. Moderate-ADpatients (baseline Mini-Mental State Examination [MMSE] 18-21) scored better on ADCS-ADL (P = .002) and ADAS-Cog (P = .05), 61% less decline both. There were no changes in mild-ADpatients (MMSE 22-26). PE-treated patients scored better on the Clinical Dementia Rating Sum of Boxes (CDR-sb) (P = .002; 71% less decline) and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) (P < .0001; 100% less decline) scales. DISCUSSION: This trial suggests that PE with albumin replacement could slow cognitive and functional decline in AD, although further studies are warranted.
Authors: Chia-Chen Liu; Jing Zhao; Yuan Fu; Yasuteru Inoue; Yingxue Ren; Yuanxin Chen; Sydney V Doss; Francis Shue; Suren Jeevaratnam; Ligia Bastea; Na Wang; Yuka A Martens; Wenhui Qiao; Minghui Wang; Na Zhao; Lin Jia; Yu Yamazaki; Akari Yamazaki; Cassandra L Rosenberg; Zhen Wang; Dehui Kong; Zonghua Li; Lindsey A Kuchenbecker; Zachary A Trottier; Lindsey Felton; Justin Rogers; Zachary S Quicksall; Cynthia Linares; Joshua Knight; Yixing Chen; Aishe Kurti; Takahisa Kanekiyo; John D Fryer; Yan W Asmann; Peter Storz; Xusheng Wang; Junmin Peng; Bin Zhang; Betty Y S Kim; Guojun Bu Journal: Nat Neurosci Date: 2022-08-01 Impact factor: 28.771
Authors: Ekaterina A Litus; Alexey S Kazakov; Evgenia I Deryusheva; Ekaterina L Nemashkalova; Marina P Shevelyova; Andrey V Machulin; Aliya A Nazipova; Maria E Permyakova; Vladimir N Uversky; Sergei E Permyakov Journal: Int J Mol Sci Date: 2022-05-31 Impact factor: 6.208
Authors: Raquel Herrero-Labrador; Angel Trueba-Saiz; Laura Martinez-Rachadell; Mᵃ Estrella Fernandez de Sevilla; Jonathan A Zegarra-Valdivia; Jaime Pignatelli; Sonia Diaz-Pacheco; Ana M Fernandez; Ignacio Torres Aleman Journal: Int J Mol Sci Date: 2020-12-18 Impact factor: 5.923
Authors: Dobri D Kiprov; Ahvie Herskowitz; Daehwan Kim; Michael Lieb; Chao Liu; Etsuko Watanabe; Jan C Hoffman; Regina Rohe; Michael J Conboy; Irina M Conboy Journal: F1000Res Date: 2021-11-24